NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e)Executive Officer Equity Awards and Goals
Effective March 9, 2018, the Board of Directors (the “Board”) of NewLink Genetics Corporation (the “Company”) approved 2018 compensation for the named executive officers for the 2018 fiscal year with respect to stock option awards. The Board also set corporate and individual goals for each of the Company’s named executive officers with respect to cash bonus targets for the 2018 fiscal year.
None of the named executive officers received a salary increase for the 2018 fiscal year. The named executive officers were awarded bonuses for 2017 equal to 90% of their respective previously-reported target bonus amounts for 2017.
Section9 – Financial Statements and Exhibits
Item 9.01.FinancialStatements and Exhibits.
(d) Exhibits.
|
ExhibitNumber |
Description |
|
10.1 |
NEWLINK GENETICS CORP ExhibitEX-10.1 2 nlnk-20180315x8kxex101.htm EXHIBIT 10.1 Exhibit Exhibit 10.1SCHEDULE OF 2018 EQUITY AWARDSNameTitle2018 Stock OptionsVesting ScheduleCharles J. Link,…To view the full exhibit click here
About NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.
